Company News
Zydus Saroglitazar Shows Stronger PBC Response in US Subgroup
Zydus Therapeutics presented new Phase 3 EPICS-III trial analysis at ACG 2026 showing saroglitazar's superior biochemical response versus placebo in PBC patients.
US subgroup showed 60.7% treatment di
